GVH disease

(redirected from Graft versus host disease)
Also found in: Medical, Acronyms.

GVH disease

 (jē′vē′āch′)
n.
Graft-versus-host disease.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Drobyski, "The role of regulatory T cells in the biology of graft versus host disease," Frontiers in Immunology, vol.
The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
(31.) Herrmann R, Sturm M, Shaw K, Pura D, Cooney J, Wright M, Phillips M, Cannell P Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
Adrian said: "It's a strange irony that the one thing I'm really worried about, my graft versus host disease, will probably play a major role in keeping me alive."
This study demonstrated that oral administration of specific antigens effectively reversed the manifestations of chronic graft versus host disease. At the same time, the treated mice were shown to have undergone a favorable change in blood chemistry promoting a naturally occurring anti-inflammatory and anti-wasting response.
Mesoblast announced that the FDA has agreed that Mesoblast can submit on a rolling basis a Biologics License Application, or BLA, for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease, or SR-aGVHD.
The company has raised funds for developing a T-cell immunotherapy product to decrease Graft versus Host Disease in hematopoietic stem cell transplantations.
Participants in the trial ("An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease") must be adults who have undergone an allogeneic hematopoietic stem cell transplant (HSCT) to treat a hematological (blood) disorder and have subsequently been diagnosed with steroid -resistant Grade II-IV GvHD.